PHASE I/II TRIAL OF CPT-11 AND TEMOZOLOMIDE IN RECURRENT MALIGNANT GLIOMA

CPT-11 和替莫唑胺治疗复发性恶性胶质瘤的 I/II 期试验

• 批准号: 7375488
• 负责人: MINESH P. MEHTA
• 金额: $ 0.09万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375488
• 关键词: PHASE; II; TRIAL; CPT; 11

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to new enrollment. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This is a Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma. Patients will receive temozolomide by mouth once a day on Days 1-5 and an infusion of irinotecan on Days 1 and 14. Treatment may be repeated every 4 weeks for up to 1 year. Patients will receive follow-up evaluations every 2 months for 1 year, every 3 months for 1 year, every 4 months for 1 year, and every 4-6 months thereafter.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项研究对新的入学率关闭。 （来自国家癌症研究所的PDQ数据库的临床试验摘要）化学疗法中使用的药物使用不同的方法来阻止肿瘤细胞分裂，从而停止生长或死亡。组合多种药物可能会杀死更多的肿瘤细胞。 这是一项I/II期试验，用于研究替莫唑胺和伊立替康在治疗患有复发性恶性神经胶质瘤的患者中的有效性。 患者每天在第1-5天每天通过口腔接受一次替莫唑胺，并在第1天和第14天注入伊立替康。可以每4周重复一次治疗，持续1年。患者将每2个月每2个月接受一次随访评估，每3个月1年，每4个月，1年，每4-6个月。